Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells

Published:2018-04-27 Issue:1 Volume:18 Page:
ISSN:1471-2466
Container-title:BMC Pulmonary Medicine
language:en
Short-container-title:BMC Pulm Med

Author:

Molina-Molina M.,Machahua-Huamani C.,Vicens-Zygmunt V.,Llatjós R.,Escobar I.,Sala-Llinas E.,Luburich-Hernaiz P.,Dorca J.,Montes-Worboys A.

Funder

Instituto de Salud Carlos III

F. Hoffmann-La Roche

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12890-018-0626-4.pdf

Reference36 articles.

1. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012;380(9842):680–8. https://doi.org/10.1016/s0140-6736(12)61144-1 . Epub 2012/08/21. PubMed PMID: 22901889.

2. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–61. https://doi.org/10.1016/s0140-6736(11)60052-4 . Epub 2011/07/02. PubMed PMID: 21719092.

3. Blaauboer ME, Boeijen FR, Emson CL, Turner SM, Zandieh-Doulabi B, Hanemaaijer R, et al. Extracellular matrix proteins: a positive feedback loop in lung fibrosis? Matrix Biol. 2014;34:170–8. https://doi.org/10.1016/j.matbio.2013.11.002 . Epub 2013/12/03. PubMed PMID: 24291458.

4. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19. https://doi.org/10.1164/rccm.201506-1063ST . Epub 2015/07/16. PubMed PMID: 26177183.

5. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9. https://doi.org/10.1016/s0140-6736(11)60405-4 . Epub 2011/05/17. PubMed PMID: 21571362.

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antioxidant, Antiinflammation, and Antifibrotic Activity of Ciplukan (Physalis angulata L). Extract;Journal of Inflammation Research;2024-09

2. Highlights on Future Treatments of IPF: Clues and Pitfalls;International Journal of Molecular Sciences;2024-08-01

3. Pharmacological Treatments and Therapeutic Targets in Muscle Dystrophies Generated by Alterations in Dystrophin-Associated Proteins;Medicina;2024-06-27

4. Investigation of the İn Vitro Effect of Vanillic Acid on Wound Healing via FN1 and COL1α1 Genes;Dicle Tıp Dergisi;2024-06-14

5. Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives;Multidisciplinary Respiratory Medicine;2024-06-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3